Pegylated liposomal doxorubicin « Medical Search of the Day
Links shared publicly online about this topic.
- 1,003total visits
Pegylated liposomal doxorubicin « Medical Search of the Day
medicalsearchoftheday.wordpress.com —
View full resource at medicalsearchoftheday.wordpress.com
Tags: Drug
Most Recently Shared on July 22, 2010 at 2:49 pm By:
Pegylated liposomal doxorubicin: Yesterday this drug name was the top search term in SearchMedica (the source of a... http://bit.ly/9jKplN
Doxorubicin hydrochloride liposome injection
fda.gov — “News Burst” View full resource at fda.gov
Most Recently Shared on February 21, 2012 at 6:38 pm By:
Today FDA announced major actions taken to bolster supply of Doxil & preservative-free formulations of methotrexate http://t.co/tBxlu57g
NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer - MarketWatch
marketwatch.com — “NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on November 22, 2011 at 6:03 am By:
Paul Cacciatore Patient Advocate
Preclin: NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combo w/Doxil in Plat.-Resist. Ovarian Cancer. http://t.co/JhJhoDzA
Oncology Article | A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients
mdlinx.com — “A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients” View full resource at mdlinx.com
Most Recently Shared on September 29, 2011 at 2:05 pm By:
Sandeep Pulim MD Health Communicator, Physician, and Doctor
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective... http://t.co/Q0GK8wmR #oncology
Oncology Article | Carboplatin Ovarian Neoplasms
mdlinx.com — “Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The Mito-2 Randomized Phase III Trial” View full resource at mdlinx.com
Most Recently Shared on August 18, 2011 at 6:19 am By:
Sandeep Pulim MD Health Communicator, Physician, and Doctor
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line trea... http://t.co/gQvyhct #oncology
Oncology Article | Ovarian Neoplasms
mdlinx.com — “Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: Current evidence and future perspectives” View full resource at mdlinx.com
Most Recently Shared on August 10, 2011 at 2:50 pm By:
Sandeep Pulim MD Health Communicator, Physician, and Doctor
Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-... http://bit.ly/nc3bK4 #oncology
Novel Agent Demonstrates Activity in Heavily Pretreated Ovarian Cancer That Progressed on Pegylated Doxorubicin
onclive.com — “A novel topoisomerase-I inhibitor designated NKTR-102 demonstrated clinically significant activity as a single agent in patients with heavily pretreated ovarian cancer who failed prior PLD.” View full resource at onclive.com
Most Recently Shared on August 1, 2011 at 2:29 pm By:
Novel Agent Demonstrates Activity in Heavily Pretreated Ovarian Cancer That Progressed on Pegylated Doxorubicin http://t.co/jz7fFD3
Johnson & Johnson Warns of Doxil (doxorubicin) Shortage - QualityPoint Technologies
qualitypointtech.net — “Johnson & Johnson has cautioned doctors not to start patients on therapy with its Doxil (doxorubicin Hcl liposome injection) because of shortages of the medicine made by an outside manufacturer. Reuters Health Information” View full resource at qualitypointtech.net
Most Recently Shared on July 22, 2011 at 9:00 pm By:
Johnson & Johnson Warns of Doxil (doxorubicin) Shortage: Johnson & Johnson has cautioned doctors not to start ... http://bit.ly/raOoxN
Oncology Article | B-cell lymphoma
mdlinx.com — “Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high life threat impact cardiopathy” View full resource at mdlinx.com
Most Recently Shared on July 18, 2011 at 9:13 am By:
Sandeep Pulim MD Health Communicator, Physician, and Doctor
Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and... http://bit.ly/o2xyVQ #oncology
Lenalidomide, bortezomib, pegylated liposomal doxo... [Blood. 2011] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on May 21, 2011 at 4:18 pm By:
Robert Z. Orlowski Doctor, Internist, and Physician
Velcade/Doxil/Revlimid/Dexamethasone shows excellent activity as initial therapy for symptomatic multiple myeloma (http://1.usa.gov/iSMsmJ).
10 Exciting Ovarian Cancer Research Topics from 2010 --" NKTR-102, AMG 386, Dose Dense Paclitaxel & Pegylated Liposomal Doxorubicin (Topics #3-5 of 10) | WORD of HOPE Podcast
wordofhopepodcast.com — “10 Exciting Ovarian Cancer Research Topics from 2010 --" NKTR-102, AMG 386, Dose Dense Paclitaxel & Pegylated Liposomal Doxorubicin (Topics #3-5 of 10) | WORD of HOPE Podcast” View full resource at wordofhopepodcast.com
Most Recently Shared on May 10, 2011 at 8:16 pm By:
Paul Cacciatore Patient Advocate
10 Exciting 2010 Ovarian Cancer Research Topics - NKTR-102, AMG 386, Dose Dense Paclitaxel & Doxil (WORD of HOPE podcast) http://dld.bz/ZxxM
NICE Unable To Recommend Ovarian Cancer Drug In Final Guidance Due To Lack Of Appropriate Evidence
medicalnewstoday.com — “In final guidance published by NICE today (27 April 2011), trabectedin (Yondelis, PharmaMar) in combination with pegylated liposomal doxorubicin hydrochloride (PLDH) is not recommended as a treatm” View full resource at medicalnewstoday.com
Most Recently Shared on April 27, 2011 at 12:04 pm By:
NICE Unable To Recommend Ovarian Cancer Drug In Final Guidance Due To Lack Of Appropriate Evidence: In final gui... http://bit.ly/i8Yvu6
NICE Unable To Recommend Ovarian Cancer Drug In Final Guidance Due To Lack Of Appropriate Evidence
medicalnewstoday.com — “In final guidance published by NICE today (27 April 2011), trabectedin (Yondelis, PharmaMar) in combination with pegylated liposomal doxorubicin hydrochloride (PLDH) is not recommended as a treatm” View full resource at medicalnewstoday.com
Most Recently Shared on April 27, 2011 at 9:05 am By:
NICE Unable To Recommend Ovarian Cancer Drug In Final Guidance Due To Lack Of Appropriate Evidence http://mnt.to/3V5p #cancer
Oncology Article | Breast cancer
mdlinx.com — “Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004--05 study” View full resource at mdlinx.com
Most Recently Shared on April 7, 2011 at 10:46 am By:
Sandeep Pulim MD Health Communicator, Physician, and Doctor
Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive ... http://bit.ly/gt8Djw #oncology
Oncology Article | Breast Neoplasms
mdlinx.com — “Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer” View full resource at mdlinx.com
Most Recently Shared on March 17, 2011 at 6:17 am By:
Sandeep Pulim MD Health Communicator, Physician, and Doctor
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperati... http://bit.ly/gVk1pN #oncology
Oncology Article | Multiple Myeloma
mdlinx.com — “Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression” View full resource at mdlinx.com
Most Recently Shared on February 18, 2011 at 9:11 am By:
Sandeep Pulim MD Health Communicator, Physician, and Doctor
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated lip... http://bit.ly/hd59Eo #oncology
Advertisement
